Stakeholder Opinions: Type 2 Diabetes in the UAE & Saudi Arabia Growth opportunities in fragmented markets
Introduction
This report focuses on the challenges of diverse and uncoordinated treatment paradigms for diabetes and the movement to rationalize efforts and establish best practice. Datamonitor uncovers the unique dynamics of the two largest diabetes markets in the GCC; including the impact of regulatory processes such as the healthcare reforms currently being undertaken.
Scope
*Description and analysis of the uniqueness of the antidiabetic markets in the UAE and Saudi Arabia
*Fragmented healthcare delivery in the UAE and Saudi Arabia presents opportunity for ramping up sales of generics and novel antidiabetic therapeutics.
*Commercial implications of Datamonitor's extensive findings and our recommendations to maximize sales in these two markets.
Highlights
Diabetes has reached near-epidemic proportions in the UAE and Saudi Arabia, with nearly one out of every five individuals suffering from diabetes in the UAE. In Saudi Arabia, the prevalence is expected to rise to between 40-50% by 2020.
The delivery of treatment for diabetes is highly fragmented, and leads to sub-optimal treatment for patients in the two countries. The fragmentation is caused by a wide variety of issues due to systemic deficiencies, regulatory changes and socio-economic factors.
Datamonitor has explained the commercial implications of its findings and developed recommendations for healthcare firms and regulators to address the many unmet needs in the treatment of diabetes and to ramp up sales and share of market in both UAE and Saudi Arabia.
Reasons to Purchase
*Gain an in-depth understanding of the two largest diabetes markets in the GCC; a strategic growth area for healthcare firms.
*Increase share of the market by effectively targeting the different segments of the population and demands; branded or generic antidiabetic agents.
*Maximize current and future revenue streams by targeting the numerous growth opportunities identified by Datamonitor.
More Research Reports
- Pricing and Reimbursement in Key Asia Pacific Markets
- Delivery Mechanisms for Large Molecule Drugs: Successes and failures of leading technologies and key drivers for market success
- The Cardiovascular Market Outlook to 2013: Competitive landscape, global market analysis and pipeline analysis
- Intellectual Property and Outsourcing in China: Minimizing risk whilst maximizing return on investment
- Health Care Equipment & Supplies: Global Industry Guide
- 2009 Trends to Watch: Healthcare Technology
- The Cancer Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Gastrointestinal, Skin, Sarcomas
- Forecast Insight: Depression - Generic induced brand erosion leads to market decline
- Stakeholder Opinions: Type 2 Diabetes in the UAE & Saudi Arabia Growth opportunities in fragmented markets





